1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Denali Therapeutics completed the sale of its Rare Pediatric Disease Priority Review Voucher to a large pharmaceutical company on July 27, 2026, receiving gross proceeds of $195.0 million at closing. The voucher was received when the FDA approved AVLAYAH (tividenofusp alfa) for Hunter syndrome in March 2026, and the sale was made under an asset purchase agreement dated June 12, 2026.
Gross proceeds of $195.0 million received from the buyer at closing on July 27, 2026
Voucher received when FDA approved AVLAYAH (tividenofusp alfa) for Hunter syndrome (MPS II) in March 2026
Sale made under asset purchase agreement dated June 12, 2026; buyer not named in the filing
Full agreement to be filed as an exhibit to a later SEC filing
Johnson & Johnson said it reached an agreement to comprehensively resolve the remaining ovarian talc litigation, covering about 76,000 claims, with a $5.5 billion commitment by the company. The deal is conditioned on participation by at least 95% of the remaining claims, and the company said it continues to deny that its talc products cause cancer.
Company commitment of $5.5 billion, with the first payment of no more than $3 billion due in 2027 and no additional payments due before 2028
Agreement conditioned on participation of at least 95% of the remaining claims, including lead plaintiff firms in federal MDL and state court cases
Announced July 27, 2026, following a July 22, 2026 MDL court order requiring plaintiffs to show why remaining claims should not be dismissed
Centene reported second-quarter 2026 results that moved from a loss a year earlier to a profit, and raised the floor of its full-year 2026 earnings guidance. The company said the increase includes about $0.50 of non-recurring items in its Medicare and Commercial segments. A director also resigned and was replaced by Paul Diaz effective July 28, 2026, and the filing states the resignation was not due to any dispute with the company.
GAAP diluted EPS was $2.19 for Q2 2026, versus a loss of $0.51 in Q2 2025; adjusted diluted EPS was $2.51, versus a loss of $0.16
Premium and service revenues rose 4% to $44.4 billion; total revenues were $53,579 million
2026 GAAP diluted EPS guidance floor raised to greater than $3.11; adjusted diluted EPS floor raised to greater than $4.80
Director Kenneth Burdick resigned effective July 28, 2026; Paul Diaz was elected to fill the vacancy and joins the Audit and Quality and Compliance Committees
Nautilus Biotechnology reported second quarter 2026 revenue of $0.2 million, its first revenue, and a net loss of $14.5 million, down from $15.0 million a year earlier. The company also said its broadscale assay will not reach general availability in 2027 at its target specifications, and it is shifting resources toward its proteoform products, which it says will not change its broader financial assumptions.
Q2 2026 revenue was $0.2 million, mainly grant revenue from The Michael J. Fox Foundation, plus service revenue from its first Iterative Mapping Early Access Program sales.
Operating expenses fell 7% to $15.9 million from $17.1 million, and net loss narrowed to $14.5 million from $15.0 million.
Broadscale assay did not meet targets for a 2027 general availability kit; the company will report a commercial timeline at a future date.
Voyager platform launch is expected in early 2027, with cash, cash equivalents and investments of $129.2 million as of June 30, 2026.
Polaris reported second quarter 2026 sales of $2,023 million, up 9% from a year earlier, and diluted EPS of $1.82 versus a loss of $1.39 per share in the prior-year quarter. The company raised its 2026 adjusted EPS guidance to $3.00 to $3.10 from $1.60 to $1.70, of which about $0.96 comes from tariff refunds recorded in the second quarter, so shareholders should weigh that one-time benefit against the higher outlook.
Q2 2026 sales were $2,023 million, up 9%; North America sales rose 11% to $1,755 million.
Reported diluted EPS was $1.82 versus a $1.39 loss a year earlier; adjusted diluted EPS was $1.97 versus $0.40.
Q2 results include $74 million of tariff refunds, which benefited adjusted EPS by $0.96.
2026 adjusted EPS guidance rose to $3.00 to $3.10 from $1.60 to $1.70; adjusted sales guidance rose to $7.30 billion to $7.50 billion from $7.15 billion to $7.30 billion.
Noble Corporation reported a second-quarter 2026 net loss of $37 million, or $0.23 per diluted share, compared with net income of $43 million, or $0.27 per share, a year earlier. Revenue fell to $720 million from $849 million, and the company reduced its full-year 2026 revenue and adjusted EBITDA guidance, mainly because of lower revenue from two rigs in Brazil, which were suspended in the quarter.
Q2 2026 total revenue was $720 million, versus $849 million in Q2 2025; diluted loss per share was $(0.23), versus diluted earnings of $0.27.
Full-year 2026 revenue guidance was cut to $2,800–$2,900 million from $2,800–$3,000 million; adjusted EBITDA guidance was cut to $850–$925 million from $940–$1,020 million.
Brazil operational suspensions reduced second-quarter contract drilling revenue by approximately $43 million.
Board approved a $0.50 per share cash dividend for Q3 2026, payable September 24, 2026, to holders of record on September 3, 2026.
At its July 21, 2026 annual meeting, stockholders of CO2 Energy Transition Corp. approved amending the charter to allow up to eleven one-month extensions of the deadline to complete a business combination, from July 22, 2026 to June 22, 2027. Following the vote, 5,869,285 shares were tendered for redemption, and each monthly extension will require a payment of $30,921.45, with the company now extended through August 22, 2026.
Annual meeting held July 21, 2026; 8,429,002 shares (87.93%) of 9,585,750 eligible shares were represented
Charter amendment approved with 6,310,067 votes for and 2,079,735 against; deadline moves from July 22, 2026 to June 22, 2027
5,869,285 shares tendered for redemption; each monthly extension payment is $30,921.45
Five directors elected, and WithumSmith+Brown, PC ratified as auditor for the year ending December 31, 2026
FirstSun Capital Bancorp reported a second-quarter 2026 net loss of $22.9 million, or $(0.49) per diluted share, compared with net income of $26.4 million, or $0.93 per diluted share, a year earlier. The company said results were affected by merger-related expenses after its April 1, 2026 acquisition of First Foundation and by two large commercial loan charge-offs. The board also authorized a share repurchase program of up to $150.0 million, which runs through June 30, 2027 and may be modified or stopped at any time.
Q2 2026 net loss of $(22.9) million, or $(0.49) per diluted share, versus net income of $26.4 million, or $0.93 per diluted share, in Q2 2025
Adjusted net income (non-GAAP) was $21.0 million, or $0.45 per diluted share, for Q2 2026
Merger-related expenses were $57.6 million and net charge-offs were $42.4 million in Q2 2026
Board authorized a repurchase program of up to $150.0 million on July 24, 2026, authorized through June 30, 2027
Sun Communities reported a second-quarter net loss to common shareholders of $992.7 million, or $8.08 per diluted share, driven by a $1.1 billion non-cash valuation charge on its UK business, which is being sold. Excluding discontinued operations, net income from continuing operations was $0.32 per diluted share, and Core FFO per share rose to $1.84 from $1.76 a year earlier, and the company raised its 2026 same property NOI growth guidance.
Net loss attributable to common shareholders of $992.7 million ($8.08 per diluted share) for the quarter ended June 30, 2026, versus net income of $1.3 billion ($10.02 per share) a year earlier
Core FFO per share of $1.84 for the quarter, up from $1.76 in the same period of 2025
Same property NOI grew 6.0% for the quarter; 2026 same property NOI growth guidance raised by 20 basis points to 4.5% to 5.3%
Park Holidays UK sale has a base consideration of about $1.04 billion, subject to UK Financial Conduct Authority approval, and is expected to close in the second half of 2026
Champions Oncology reported record fiscal 2026 revenue of $59.4 million, up 4% from $56.9 million, for the year ended April 30, 2026. The company swung to a net loss of $1.2 million, compared with net income of $4.7 million a year earlier, as operating costs rose and the prior year's $4.5 million data license revenue did not recur.
Fiscal 2026 oncology revenue was $59.4 million, up 4% from $56.9 million; the prior year included about $4.5 million of data license revenue that did not recur.
Net loss was $1.2 million for fiscal 2026 versus net income of $4.7 million in fiscal 2025; adjusted EBITDA was $1.6 million versus $7.1 million.
Fourth quarter revenue was $13.8 million, up 12% from $12.4 million, and the quarterly net loss narrowed to $667,000 from $1.8 million.
Cash was $4.9 million at April 30, 2026, with no debt, down from $9.8 million a year earlier.
Lattice Semiconductor completed its acquisition of AMI on July 27, 2026, paying about $1 billion in cash and about 5.2 million shares and restricted stock units, subject to closing adjustments. The cash was funded from cash on hand and a $925.0 million term loan borrowed under the company's credit agreement, so the deal adds significant debt and share issuance for shareholders to weigh. The filing gives no AMI financial results; the company says it will provide them with its second quarter 2026 results on August 4, 2026.
Total consideration of about $1 billion in cash plus about 5.2 million shares and restricted stock units, subject to adjustments.
On July 27, 2026, Lattice borrowed $925.0 million under the delayed draw term loan facility to fund the cash consideration.
On July 27, 2026, Lattice issued 4,741,352 shares of common stock to the AMI sellers, with transfer restrictions releasing 25% per 90-day period.
The company will report AMI operating results with its second quarter 2026 results on August 4, 2026.
Simpson Manufacturing reported second-quarter 2026 net sales of $671.1 million, up 6.3%, and diluted earnings per share of $3.09, up from $2.47 a year earlier. The company also raised its 2026 share repurchase authorization to $200.0 million and updated its full-year 2026 outlook, which for shareholders means higher reported profit and more capacity for buybacks.
Net sales of $671.1 million rose 6.3%, with North America up 6.0% and Europe up 7.6%.
Income from operations of $169.1 million rose 20.6%; operating margin was 25.2%, including a 100 basis point benefit from a $5.5 million eminent domain settlement.
On July 23, 2026, the Board raised the 2026 share repurchase authorization from $150.0 million to $200.0 million; the company repurchased $48.7 million of stock in the quarter.
Updated 2026 outlook: consolidated operating margin of 19.7% to 20.5% and capital expenditures of $80.0 million to $90.0 million. The filing does not state the prior outlook.
UDR reported second-quarter 2026 net income of $0.21 per diluted share, up from $0.11 a year earlier, while FFO per diluted share fell to $0.60 from $0.61 and FFOA was flat at $0.64. The company raised its full-year 2026 guidance for same-store revenue, same-store NOI and FFOA per share, but lowered the midpoint of its FFO per share guidance by $0.02. Shareholders also get a switch to monthly dividends of $0.145 per share starting in July 2026.
Q2 2026 net income per diluted share was $0.21 versus $0.11 in Q2 2025; year-to-date was $0.79 versus $0.34.
Full-year 2026 FFOA per diluted share guidance is now $2.49 to $2.57, up from $2.47 to $2.57; FFO guidance is $2.47 to $2.55, down from $2.48 to $2.58.
Same-store revenue growth guidance is 0.75% to 2.00%, up from 0.25% to 2.25%.
The first monthly dividend of $0.145 per share is payable July 31, 2026; Q2 dividends totaled $0.435 per share.
Element Solutions reported second-quarter 2026 net sales of $978 million, up 56% on a reported basis and 15% organically, with GAAP net income of $77 million, or $0.32 per diluted share, versus $48 million, or $0.20, a year earlier. The company raised its full-year 2026 adjusted EBITDA guidance to $690 million to $710 million, but the results come alongside a July 6, 2026 merger agreement under which Solstice would acquire the company for 0.5 Solstice shares and $10.00 in cash per share.
Q2 2026 adjusted EBITDA was $184 million, up 35% on a reported basis, with adjusted EBITDA margin of 27.8% versus 26.6% a year earlier.
Full-year 2026 adjusted EBITDA guidance is $690 million to $710 million, and third-quarter adjusted EBITDA is expected to be about $180 million.
Under the July 6, 2026 merger agreement, each share would be exchanged for 0.5 shares of Solstice common stock and $10.00 in cash; closing is expected in the first half of 2027.
Kymera Therapeutics said Chief Medical Officer Jared Gollob resigned on July 27, 2026, for personal reasons, and will stay on as an advisor through December 31, 2026. Terence Rooney, M.D., formerly an immunology leader at Johnson & Johnson, became CMO effective the same day. The change is a senior management transition that leads clinical development for the company's oral immunology pipeline.
Jared Gollob resigned as Chief Medical Officer on July 27, 2026, after eight years with the company, citing personal reasons
Terence Rooney, M.D., succeeds Gollob as CMO effective July 27, 2026
Gollob will continue as an advisor until December 31, 2026
Rooney previously served as Senior Vice President, Portfolio and Asset Management Leader, Immunology, at Johnson & Johnson
F5 reported fiscal third-quarter 2026 revenue of $865 million, up 11% from $780 million a year earlier, and GAAP diluted earnings of $3.62 per share versus $3.25. The company raised its fiscal 2026 revenue growth and non-GAAP earnings per share guidance, which gives shareholders a higher expected range for the full year.
Third-quarter revenue was $865 million, up 11%; product revenue grew 19% and systems revenue grew 32%.
GAAP diluted EPS was $3.62 versus $3.25; non-GAAP diluted EPS was $4.73 versus $4.16.
Fiscal 2026 revenue growth guidance was raised to 9% to 10% from 7% to 8%.
Fiscal 2026 non-GAAP EPS guidance was raised to $17.21 to $17.33 from $16.25 to $16.55; fourth-quarter revenue is guided to $870 million to $890 million.
On July 21, 2026, Boston Scientific's board approved a new global restructuring program with estimated total pre-tax charges of $700 million to $800 million, of which $600 million to $700 million is expected to be cash outlays. The company expects the plan to reduce gross annual pre-tax expenses by about $500 million, with a substantial portion reinvested in growth, and it expects some headcount reductions.
Board approved the 2026 Restructuring Plan on July 21, 2026; activities start in 2026 and are expected to be substantially complete by the end of 2029.
Estimated total pre-tax charges of $700 million to $800 million, including $600 million to $700 million in future cash outlays.
Charges by type: transfer costs $300 million to $350 million, termination benefits $275 million to $300 million, and other costs $125 million to $150 million.
Expected reduction in gross annual pre-tax expenses of about $500 million as program benefits are realized.
Welltower reported second-quarter 2026 revenue of $3.54 billion, up from $2.55 billion a year earlier, and diluted net income of $0.61 per share, up from $0.45. The company raised its 2026 normalized FFO guidance but cut its 2026 net income guidance, and it increased its quarterly dividend 15% to $0.85.
Diluted net income attributable to common stockholders was $0.61 per share, compared with $0.45 a year earlier; total revenues were $3.54 billion, compared with $2.55 billion.
Normalized FFO attributable to common stockholders was $1.60 per diluted share, up 25.0% from $1.28 a year earlier.
2026 normalized FFO guidance was raised to $6.36 to $6.44 per diluted share from $6.21 to $6.35; net income guidance was cut to $3.11 to $3.19 from $3.24 to $3.38.
The quarterly dividend was raised 15% to $0.85 per share, payable August 20, 2026 to holders of record on August 12, 2026.
Agilysys reported fiscal 2027 first-quarter revenue of $87.7 million, up 14.3% from $76.7 million a year earlier, and net income of $9.0 million, or $0.32 per diluted share, versus $4.9 million, or $0.17, a year earlier. The company raised its full-year fiscal 2027 total revenue guidance to $368 million to $373 million from $365 million to $370 million, which signals stronger expected sales for shareholders.
Total net revenue rose 14.3% to $87.7 million; subscription revenue grew 26.1% year over year.
Net income was $9.0 million, or $0.32 per diluted share, compared with $4.9 million, or $0.17, a year earlier.
Full-year fiscal 2027 total revenue guidance raised to $368 million to $373 million; subscription revenue growth guidance raised to at least 32% from at least 30%.
Free cash flow (non-GAAP) was $7.3 million, compared with negative $5.0 million a year earlier.
Sanmina reported fiscal third-quarter 2026 results for the quarter ended June 27, 2026, with revenue of $3.46 billion versus $2.04 billion a year earlier and non-GAAP diluted EPS of $3.31 versus $1.53. The company lowered its fiscal 2026 non-GAAP diluted EPS outlook to $10.75-$11.35 from $11.90-$12.20, which matters to shareholders because the full-year profit forecast is now lower even though the quarter was stronger.
Q3 revenue $3.46 billion vs. $2.04 billion a year earlier; GAAP diluted EPS $2.12 vs. $1.26
Fiscal 2026 non-GAAP diluted EPS outlook cut to $10.75-$11.35 from $11.90-$12.20; revenue range now $13.7 billion-$14.3 billion vs. $14.0 billion-$14.3 billion
Q3 cash flow from operations $124 million; free cash flow $24 million
Brixmor reported second-quarter 2026 results with total revenues of $354.2 million, up from $339.5 million a year earlier, and Nareit FFO per diluted share of $0.58, up from $0.56. GAAP net income attributable to the company per diluted share fell to $0.24 from $0.28, and the company raised its 2026 Nareit FFO per share range to $2.35 to $2.37 from $2.34 to $2.37.
Net income attributable to Brixmor was $73.5 million, or $0.24 per diluted share, versus $85.1 million, or $0.28, in the second quarter of 2025.
Nareit FFO was $178.6 million, or $0.58 per diluted share, versus $171.5 million, or $0.56, a year earlier.
2026 guidance: Nareit FFO per diluted share of $2.35 to $2.37 (from $2.34 to $2.37), and same property NOI growth of 5.00% to 5.75% (from 4.75% to 5.50%).
The Board declared a quarterly dividend of $0.3075 per share, payable October 15, 2026 to holders of record on October 2, 2026.
Cadence reported second-quarter 2026 revenue of $1.584 billion, up from $1.275 billion a year earlier, and GAAP diluted EPS of $1.33 versus $0.59. The company raised its full-year 2026 revenue and non-GAAP EPS outlook and reported a record backlog of $8.1 billion, which signals higher expected revenue and earnings for shareholders.
Q2 2026 GAAP diluted EPS was $1.33 versus $0.59 in Q2 2025; non-GAAP diluted EPS was $2.11 versus $1.65.
FY 2026 revenue outlook raised to $6.26 billion to $6.34 billion; non-GAAP EPS outlook raised to $8.05 to $8.15.
Quarter-end backlog was a record $8.1 billion.
Q3 2026 revenue outlook is $1.595 billion to $1.625 billion, and the company expects to use about $200 million to repurchase shares in Q3.
Cracker Barrel said David Deno, former CEO of Bloomin' Brands, will become President and Chief Executive Officer and join the Board effective August 10, 2026, succeeding Julie Masino, who will also leave the Board. Masino will remain an employee until October 9, 2026 to assist the transition. The filing contains no financial results, so the leadership change is the main development for shareholders.
David Deno, age 69, was CEO of Bloomin' Brands from April 2019 to September 2024 and will become Cracker Barrel's CEO on August 10, 2026.
Deno's employment agreement sets a base salary of $1,000,000, an initial annual bonus target of 125% of base salary, and an initial long-term incentive target of 360% of base salary.
Deno will receive a one-time sign-on award of $200,000 in restricted stock units and $200,000 in stock options, vesting on the third anniversary of the grant date.
Masino's Transition Agreement provides separation payments and equity treatment consistent with a termination without Cause under her July 17, 2023 employment agreement.
Sarepta Therapeutics appointed Michael Severino, M.D., former CEO of Tessera Therapeutics, as chief executive officer effective July 28, 2026, and as a Class I director. Doug Ingram, the current CEO, departs as CEO and board member on that date and will serve as a consultant until December 31, 2026. The filing describes a sign-on equity package with a grant date value of approximately $35 million and a base salary of $1,180,000, which shareholders may track for compensation and leadership continuity.
Michael Severino, M.D., becomes CEO and a director effective July 28, 2026, succeeding Doug Ingram
Sign-on equity grant has an approximate grant date value of $35,000,000, including a $14,000,000 make-whole grant
Severino's employment agreement sets an annual base salary of $1,180,000 and a target bonus of 110% of base salary
Ingram will consult for the company until December 31, 2026, for a monthly fee of $15,000
Solstice Advanced Materials and its consenting lenders signed an amendment on July 24, 2026 to its existing credit agreement with JPMorgan Chase Bank, N.A. as administrative agent. The amendment allows, among other things, $4.685 billion in bridge financing tied to a merger agreement dated July 6, 2026 with Element Solutions Inc. and related merger subsidiaries.
Amendment dated July 24, 2026 to the credit agreement originally dated October 29, 2025
Permits $4.685 billion in bridge financing to Solstice and other transactions linked to the merger
Merger agreement dated July 6, 2026 with Element Solutions Inc. and two wholly-owned Solstice merger subsidiaries
Full amendment filed as Exhibit 10.1; some schedules and exhibits omitted under Regulation S-K Item 601(a)(5)
SPAC Research Alliance Corporation III (RACC) signed a business combination agreement on July 26, 2026 to acquire 100% of OHB Pediatrics Ltd., doing business as Oak Hill Bio, in exchange for newly issued RACC common stock. The combined company would be renamed Oak Hill Bio, Inc. and trade on Nasdaq as OAKH, with closing expected by year-end 2026 subject to shareholder approval and other conditions.
Base equity value of $160 million, plus a SAFE amount, divided by $10.00 per share sets the share count issued to Oak Hill Bio shareholders
Expected gross proceeds of about $175 million, including $75 million from RACC's trust account backstopped by RA Capital and a $100 million private financing
RACC shareholders may redeem Class A shares for cash from the trust account in connection with the transaction
Either party may terminate if the deal is not closed within six months of the agreement date, subject to extension provisions
Novanta completed its acquisition of Riverpoint Medical on July 23, 2026, paying the seller approximately $1.2 billion in cash, subject to customary adjustments, with a further $250.0 million milestone payment due by January 8, 2027. The company funded the deal by borrowing $616.0 million under its credit facilities and using cash on hand, bringing consolidated debt to $854.7 million as of July 22, 2026. The company expects the deal to add $0.18 to $0.25 of adjusted earnings per share in 2027, its first full year after closing.
Closed July 23, 2026, with approximately $1.2 billion paid in cash at closing
$250.0 million milestone payment remains payable to the seller on or before January 8, 2027
$616.0 million borrowed under revolving and delayed draw term loan facilities; consolidated debt $854.7 million as of July 22, 2026
Expected to contribute $0.18 to $0.25 of adjusted EPS in 2027; 2026 impact to be discussed on the second quarter earnings call
The FDA approved Freenome's SimpleScreen CRC, a blood-based colorectal cancer screening test for adults 45 and older at average risk. Under an August 2025 agreement, Freenome will receive a $100 million milestone payment from Abbott, which will exclusively commercialize the test in the U.S. this fall.
FDA approved SimpleScreen CRC for adults 45 and older at average risk for colorectal cancer, announced July 27, 2026.
In the PREEMPT CRC study of more than 48,000 adults, the test showed 81.1% sensitivity for colorectal cancer and 90.4% specificity for advanced colorectal neoplasia.
Freenome will receive a $100 million milestone payment from Abbott for the FDA approval; Abbott plans to commercialize the test in the U.S. this fall.
Alpha Metallurgical Resources reported preliminary second-quarter 2026 results showing a net loss of $12.3 million, or $0.96 per diluted share, and Adjusted EBITDA of $25.6 million on 3.5 million tons sold. The company lowered its 2026 metallurgical coal sales volume guidance and raised its cost of coal sales guidance, citing weak met coal markets and equipment damage at Dominion Terminal Associates, which lowers expected volumes and raises costs for shareholders.
Preliminary Q2 2026 net loss of $12.3 million, or $0.96 per diluted share; Adjusted EBITDA of $25.6 million
2026 metallurgical coal sales volume guidance cut to 13.2 million to 14.0 million tons, from 14.4 million to 15.4 million tons
2026 cost of coal sales guidance raised to $103.00 to $107.00 per ton, from $95.00 to $101.00
Definitive second-quarter results and operational update due August 7, 2026; results are preliminary and may change
Cadiz said Chief Financial Officer Stanley Speer will retire effective September 1, 2026, and Jacinto J. Hernandez, currently Executive Vice President of Finance, will become CFO on that date. Speer will serve as an advisor through December 31, 2026, and his separation terms include accelerated vesting of restricted stock units and a new grant tied to the Northern Pipeline project financing.
Stanley E. Speer retires as CFO effective September 1, 2026, and advises the company through December 31, 2026 at $10,000 per month.
Jacinto J. Hernandez, age 47, has an annual base salary of $400,000 and a cash bonus target of 100% of salary.
Hernandez's inducement awards total 800,000 restricted stock units and 800,000 performance stock units, subject to Compensation Committee approval.
MapLight Therapeutics reported topline results from ZEPHYR, a Phase 2 trial of ML-007C-MA in hospitalized adults with schizophrenia experiencing an acute exacerbation of psychosis, on July 27, 2026. The 210/3 mg twice-daily dose met the primary endpoint, reducing PANSS total score by 4.5 points more than placebo at Week 5, while the 330/6 mg once-daily arm did not reach statistical significance. The company plans to discuss next steps with the FDA at an end-of-phase 2 meeting before a further pivotal trial.
210/3 mg BID arm: PANSS total score down 4.5 points versus placebo at Week 5 (p=0.015), meeting the primary endpoint
330/6 mg QD arm: 2.8 points versus placebo, p=0.110, not statistically significant
Prespecified cognitive composite score improved in the baseline-impaired subgroup (effect size 0.51, p=0.041)
Company plans to engage the FDA at an end-of-phase 2 meeting and identify sites for an additional pivotal trial
The Ensign Group reported second-quarter 2026 GAAP diluted earnings of $1.68 per share, up from $1.44 a year earlier, and adjusted earnings of $1.92 per share, up from $1.59. It raised its 2026 earnings guidance to $7.75 to $7.85 per diluted share from $7.48 to $7.62, and its revenue guidance to $5.87 billion to $5.92 billion from $5.81 billion to $5.86 billion, which matters to shareholders because it signals stronger expected profit and sales for the full year.
Q2 2026 GAAP diluted EPS was $1.68, versus $1.44 in Q2 2025; net income attributable to the company was $99.7 million
Consolidated revenue was $1.44 billion for the quarter, up 17.3% from the prior year quarter
2026 diluted EPS guidance raised to $7.75 to $7.85 from $7.48 to $7.62
2026 revenue guidance raised to $5.87 billion to $5.92 billion from $5.81 billion to $5.86 billion
Baker Hughes reported second-quarter 2026 revenue of $6,742 million, down 2% from a year earlier, and GAAP net income of $681 million, down 3%. Adjusted EBITDA rose 2% to $1,231 million, and orders reached $10.5 billion, up 49%, with the company raising its full-year IET order outlook to more than $45 billion. For shareholders, the year-over-year sales and GAAP profit declines contrast with stronger orders, adjusted profit and a larger order outlook.
Revenue was $6,742 million, up 2% sequentially and down 2% year over year; GAAP diluted EPS was $0.68 versus $0.71 a year earlier.
Adjusted diluted EPS was $0.64, up from $0.63 in the second quarter of 2025; adjusted EBITDA was $1,231 million.
IET orders were $7,088 million, and the company raised its Horizon 2 (2026-2028) IET orders outlook to more than $45 billion.
The Chart Industries acquisition closed in July 2026, and the sale of Waygate Technologies to Hexagon was announced for about $1.45 billion before closing adjustments.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.